<DOC>
	<DOC>NCT00911222</DOC>
	<brief_summary>The purpose of this registry is to record information on reality of anti-emetic therapies of cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic therapies dependent on the rate "complete and major control" of nausea and emesis in moderately and highly emetogenic chemotherapies, consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.</brief_summary>
	<brief_title>Epidemiological EMESIS-Registry</brief_title>
	<detailed_description />
	<mesh_term>Antiemetics</mesh_term>
	<criteria>Moderately or highly emetogenic chemotherapy consisting of platinderivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid. start with the 1st cycle of the regimen (chemo naive patients). Inclusion of pretreated patients is also possible, if the last treatment cycle of a previous chemotherapy was given &gt;= 24 months ago. Compliance with registry procedures Age &gt;= 18 years WHO Performance Status of 0 or 1 (KarnofskyIndex &gt;= 70%) Life expectancy of at least 12 weeks Signed and dated informed consent before the start of the registry Mentally incapable or incompliant patients Last chemotherapy &lt;= 24 months (if pretreated) Known hypersensitivity to antiemetic medication unability of the patient to be treated with oral medication pregnancy or lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>antiemetic therapy</keyword>
	<keyword>emesis</keyword>
	<keyword>vomiting</keyword>
	<keyword>nausea</keyword>
	<keyword>moderately and highly emetogenic chemotherapy</keyword>
	<keyword>cisplatin</keyword>
	<keyword>carboplatin</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>anthracycline</keyword>
	<keyword>cyclophosphamid</keyword>
</DOC>